Daptomycin Concentration in Drainage Fluid and Blood Samples of ICU Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03004066

Enrollment

Registered

2016-12-28

Start date

2016-10-31

Completion date

2019-03-31

Last updated

2019-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Assist Device

Brief summary

10 patients with chronic heart failure receiving daptomycin therapy after implantation of a left ventricular heart assist system. Measurement of daptomycin levels in drainage fluids (mediastinal and pleural drainage systems) and in blood samples.

Interventions

DRUGDaptomycin

standard care

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* written consent * heart assist device implantation * wound drainage * daptomycin therapy

Exclusion criteria

* pregnancy * no written consent possible * absence of wound drainage * allergy to study medication * acute rhabdomyolysis

Design outcomes

Primary

Measure	Time frame	Description
levels of Daptomycin in drainage fluid	4 days	Pharmacokinetics of Daptomycin in intensive care patients with wound drainage after surgery (LVAD implantation)
levels of Daptomycin in blood samples	4 days	Pharmacokinetics of Daptomycin in intensive care patients after surgery (LVAD implantation)

Secondary

Measure	Time frame	Description
infections	14 days	incidence of gram-positive infections

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026